Floatz logo

Carboplatin

Portal Vein Tumor Thrombus

First Affiliated Hospital of Guangxi Medical UniversitySmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Portal Vein Tumor Thrombus cohort.

Asset / SponsorPhaseRating
Sorafenib
First Affiliated Hospital of Zhejiang University
Phase 4BBB
LENVATINIB
First Hospital of China Medical University
Phase 4BBB
Epirubicin
Shanghai Zhongshan Hospital
Phase 3B
Ethiodized Oil
Shanghai Zhongshan Hospital
Phase 3B
ABSORBABLE GELATIN SPONGE
Shanghai Zhongshan Hospital
Phase 3B

View all 9 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →